Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Roderick Walker
Protocol for the P3BEP Trial (ANZUP 1302): An International Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Paediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours
BMC Cancer
Cancer Research
Oncology
Genetics
Should Active Recruitment of Health Workers From Sub-Saharan Africa Be Viewed as a Crime?
The Lancet
Medicine
Related publications
Accelerated BEP: A Phase I Trial of Dose-Dense BEP for Intermediate and Poor Prognosis Metastatic Germ Cell Tumour
British Journal of Cancer
Cancer Research
Oncology
Is CBOP/BEP an Alternative to BEP for Patients With Poor Prognosis Metastatic Germ Cell Tumours?
ESMO Open
Cancer Research
Oncology
Familial Predisposition to Both Male and Female Germ Cell Tumours?
Journal of Medical Genetics
Genetics
The CLOSED Trial; CLOnidine Compared With Midazolam for SEDation of Paediatric Patients in the Intensive Care Unit: Study Protocol for a Multicentre Randomised Controlled Trial
BMJ Open
Medicine
Does Intensive Management Improve Remission Rates in Patients With Intermediate Rheumatoid Arthritis? (The TITRATE Trial): Study Protocol for a Randomised Controlled Trial
Trials
Medicine
Pharmacology
Multidisciplinary and Multifaceted Outpatient Management of Patients With Osteoarthritis: Protocol for a Randomised, Controlled Trial
BMC Musculoskeletal Disorders
Rheumatology
Orthopedics
Sports Medicine
Randomized Trial of Legflow® Paclitaxel Eluting Balloon and Stenting Versus Standard Percutaneous Transluminal Angioplasty and Stenting for the Treatment of Intermediate and Long Lesions of the Superficial Femoral Artery (RAPID Trial): Study Protocol for a Randomized Controlled Trial
Trials
Medicine
Pharmacology
Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial
The Lancet
Medicine
Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial
The Lancet
Medicine